Suppr超能文献

[新辅助放化疗后局部晚期直肠癌患者生存预测因素的评估]

[Assessment of predictive factors for survival in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy].

作者信息

Wu G J, Yu T, Jia W W, An Q, Xiao G, Wang X

机构信息

Department of General Surgery, Beijing Hospital, National Center of Gerontology, Beijing 100730, China.

出版信息

Zhonghua Yi Xue Za Zhi. 2017 Mar 14;97(10):739-742. doi: 10.3760/cma.j.issn.0376-2491.2017.10.005.

Abstract

To evaluate the clinical predictive factors for survival prognosis in patients with locally advanced rectal cancer after neoadjuvant chemoradiotheraphy. The study included 87 patients with middle and lower locally advanced rectal cancer, who underwent neoadjuvant chemoradiotheraphy followed by radical surgery between April 2007 and May 2015. The clinical factors associated with 3-year disease-free survival (DFS) and overall survival (OS) were analyzed.Kaplan-Meier analysis of disease-free survival and overall survival was performed for all patients. The 3-year DFS was significantly improved in patients with negative lymph node(95.2% vs 69.5%, χ(2)=8.642, =0.003). The 3-year OS was better in the patients with lower serum level of pre- chemoradiotheraphy carcino-embryonic antigen (CEA)(90.9% vs 66.7%, χ(2)=8.820, =0.003). Cox regression multivariate analysis revealed that serum level of pre-chemoradiotheraphy CEA was an independent predictive factor for 3-year OS(=0.035). Serum level of pre- chemoradiotheraphy CEA is an independent risk factor for 3-year OS.

摘要

评估局部晚期直肠癌患者新辅助放化疗后生存预后的临床预测因素。该研究纳入了87例中低位局部晚期直肠癌患者,这些患者于2007年4月至2015年5月期间接受了新辅助放化疗,随后进行了根治性手术。分析了与3年无病生存(DFS)和总生存(OS)相关的临床因素。对所有患者进行了无病生存和总生存的Kaplan-Meier分析。淋巴结阴性患者的3年DFS显著改善(95.2%对69.5%,χ(2)=8.642,P=0.003)。放化疗前血清癌胚抗原(CEA)水平较低的患者3年OS更好(90.9%对66.7%,χ(2)=8.820,P=0.003)。Cox回归多因素分析显示,放化疗前CEA血清水平是3年OS的独立预测因素(P=0.035)。放化疗前CEA血清水平是3年OS的独立危险因素。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验